Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

References

• Swann J B, Smyth M J. Immune surveillance of tumors. J Clin Invest 2007; 117: 1137–1146
   PubMed Web of Science ®Google Scholar
• Wahlin B E, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007; 13(2 Part 1)388–397
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960–1964
   PubMed Web of Science ®Google Scholar
• Dudley M E, Wunderlich J R, Robbins P F, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850–854
   PubMed Web of Science ®Google Scholar
• Dudley M E, Yang J C, Sherry R, Hughes M S, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233–5239
   PubMed Web of Science ®Google Scholar
• Ferrone S, Whiteside T L. Tumor microenvironment and immune escape. Surg Oncol Clin N Am 2007; 16: 755–774, viii
   PubMed Web of Science ®Google Scholar
• Rabinovich G A, Gabrilovich D, Sotomayor M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Scheibenbogen C, Schaller G, Leigh B, Schmittel A, Letsch A, et al. Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. Int J Cancer 2003; 105: 221–225
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Scheibenbogen C, Letsch A, et al. T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. J Transl Med 2005; 3: 3
   PubMed Web of Science ®Google Scholar
• Baeuerle P A, Reinhardt C, Kufer P. BiTE: a new class of antibodies that recruit T-cells. Drugs Future 2008; 33: 137
   Web of Science ®Google Scholar
• Dreier T, Baeuerle P A, Fichtner I, Grün M, Schlereth B, Lorenczewski G, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol 2003; 170: 4397–4402
   PubMed Web of Science ®Google Scholar
• Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 2006; 55: 503–514
   PubMed Web of Science ®Google Scholar
• Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle P A. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43: 763–771
   PubMed Web of Science ®Google Scholar
• Sato S, Hasegawa M, Fujimoto M, Tedder T F, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000; 165: 6635–6643
   PubMed Web of Science ®Google Scholar
• d'Argouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009; 33: 465–473
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974–977
   PubMed Web of Science ®Google Scholar
• Topp M S, Goekbuget N, Kufer P, Zugmaier G, Degenhard E, Neumann S, et al. Treatment with anti-CD19 BiTE antibody blinatumomab (MT103 /MEDI-538) is able to eliminate minimal residual disease (MRD) in patients with B-Precursor acute lymphoblastic leukemia (ALL): First Results of an Ongoing Phase II Study. Blood 2008; 112(Suppl)1926, (abstract)
   Google Scholar
• Bargou R, Kufer P, Goebeler M, Knop S, Einsele H, Noppeney R, et al. Sustained response duration seen after treatment with single agent blinatumomab (MT103/MEDI-538)in the ongoing phase I study MT103-104 in patients with relapsed NHL. Blood 2008; 112(Suppl)267, (Abstract)
   Google Scholar
• Baeuerle P A, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009; 11: 22–30
   PubMedGoogle Scholar